[Source: CNN Money] – For at least a decade, anyone following the life sciences industry has noticed two naked truths.
One is that the biggest pharmaceutical companies are struggling to replenish research development pipelines as their billion-dollar blockbuster drugs go off patent and in-house programs falter, all despite having spent billions on research and development.
The other is that biotechnology companies often have the best ideas for new drugs but are constantly short of cash.
For more information: Pharma and biotech: is there love?